Literature DB >> 25457476

Cardiac resynchronization therapy in patients with atrial fibrillation: a meta-analysis.

Cláudia Lopes1, Telmo Pereira, Sérgio Barra.   

Abstract

BACKGROUND AND
OBJECTIVE: To combine the results of the best scientific evidence in order to compare the effects of cardiac resynchronization therapy (CRT) in heart failure patients with atrial fibrillation (AF) and in sinus rhythm (SR) and to determine the effect of atrioventricular nodal ablation in AF patients.
METHODS: The electronic databases PubMed, B-On and Cochrane CENTRAL were searched, and manual searches were performed, for randomized controlled trials and cohort studies up to November 2012. The endpoints analyzed were all-cause and cardiovascular mortality and response to CRT.
RESULTS: We included 19 studies involving 5324 patients: 1399 in AF and 3925 in SR. All-cause mortality was more likely in patients with AF compared to patients in SR (OR = 1.69; 95% CI: 1.20–2.37; p = 0.002). There were no statistically significant differences in cardiovascular mortality (OR = 1.36; 95% CI: 0.92–2.01; p = 0.12). AF was associated with an increased likelihood of lack of response to CRT (OR = 1.41; 95% CI: 1.15–1.73; p = 0.001). Among subjects with AF, ablation of the atrioventricular node was associated with a reduction in all-cause mortality (OR = 0.42; 95% CI: 0.22–0.80; p = 0.008), cardiovascular death (OR = 0.39; 95% CI: 0.20–0.75; p = 0.005) and the number of non-responders to CRT (OR = 0.30; 95% CI: 0.10–0.90; p = 0.03).
CONCLUSIONS: The presence of AF is associated with increased likelihood of all-cause death and non-response to CRT, compared to patients in SR. However, many patients with AF benefit from CRT. Atrioventricular nodal ablation appears to increase the benefits of CRT in patients with AF.

Entities:  

Mesh:

Year:  2014        PMID: 25457476     DOI: 10.1016/j.repc.2014.05.008

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  7 in total

Review 1.  Comparison of survival for cardiac resynchronization therapy in atrial fibrillation patients with or without atrio-ventricular junction ablation and patients in sinus rhythm: a systematic review and network meta-analysis.

Authors:  Yangjing Xue; Jinsheng Wang; Jiaoni Wang; Saroj Thapa; Kaiyu Huang; Yangpei Peng; Lu Qian; Jiwu Li; Kangting Ji
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

2.  Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition.

Authors:  Antonis S Manolis; Theodora A Manolis; Antonis A Manolis; Helen Melita
Journal:  Heart Fail Rev       Date:  2022-03-23       Impact factor: 4.654

Review 3.  Heart failure and atrial fibrillation: from basic science to clinical practice.

Authors:  João Pedro Ferreira; Mário Santos
Journal:  Int J Mol Sci       Date:  2015-01-30       Impact factor: 5.923

4.  Outcomes of cardiac resynchronisation therapy in patients with heart failure with atrial fibrillation: a systematic review and meta-analysis of observational studies.

Authors:  Usman Mustafa; Jessica Atkins; George Mina; Desiree Dawson; Catherine Vanchiere; Narendra Duddyala; Ryan Jones; Pratap Reddy; Paari Dominic
Journal:  Open Heart       Date:  2019-03-19

5.  Atrial fibrillation incidence and impact of biventricular pacing on long-term outcome in patients with heart failure treated with cardiac resynchronization therapy.

Authors:  Jonatan Jacobsson; Christian Reitan; Jonas Carlson; Rasmus Borgquist; Pyotr G Platonov
Journal:  BMC Cardiovasc Disord       Date:  2019-08-13       Impact factor: 2.298

6.  Pacemaker and Atrioventricular Junction Ablation in Patients With Atrial Fibrillation-A Systematic Review of Systematic Review and Meta-Analysis.

Authors:  Chi Zhang; Xi-Ying Wang; Lian Lou; Xuan Zhang; Le-Le Chen; Yu-Xiao Chen; Jian Yang
Journal:  Front Cardiovasc Med       Date:  2022-01-20

7.  Systematic reviews and meta-analysis published in indexed Portuguese medical journals: time trends and critical appraisal.

Authors:  Luísa Prada; Ana Prada; Miguel Marques Antunes; Ricardo M Fernandes; João Costa; Joaquim J Ferreira; Daniel Caldeira
Journal:  BMC Med Res Methodol       Date:  2022-04-10       Impact factor: 4.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.